Abatacept is best described as which type of immunomodulator?

• A. T cell co-stimulation modulator
• B. B cell modulator
• C. TNF-alpha inhibitor
• D. JAK inhibitor

Answer: (A)

Abatacept works by blocking the second signal required for full T-cell activation. It’s a fusion protein combining CTLA-4 with an IgG1 Fc region, which binds to the costimulatory molecules CD80 and CD86 on antigen-presenting cells. When these molecules are occupied, CD28 on T cells cannot engage them, so T cells don’t receive the critical costimulatory signal and fail to become fully activated. This reduces T-cell proliferation and downstream inflammatory cytokine production, dampening the immune response.

This mechanism is different from other immunomodulators: a B-cell modulator targets B cells (for example, depleting them), a TNF-α inhibitor blocks the inflammatory cytokine TNF-α, and a JAK inhibitor blocks JAK-STAT signaling inside cells. Abatacept specifically interferes with T-cell costimulation rather than directly affecting B cells, TNF-α, or JAK signaling.